FIELD

The present disclosure relates to a topical skin cream composition that is formulated to assist with the rejuvenation of human skin.

BACKGROUND

Human skin is exposed to many stressors that lead to an ageing effect of the skin over the course of time. Such stressors include air-conditioning, heating, pollution, poor hydration, poor nutrition, exposure to the elements, and exposure to the sun. Progressively, such stressors lead to an acceleration of the ageing process and a reduction in the elasticity and firmness, the presence of age spots, wrinkles, and skin discolouration. A skin that can maintain its rejuvenation processes effectively is able to minimize and/or reduce the onset of such deleterious effects.

Accordingly, it will be readily appreciated that a topical skin cream composition, which may be understood to include a body cream, a body lotion, a body mask, a cold cream, a concealing cream, an eye cream, a facial mask, Galen’s wax, a lip balm, a moisturiser for skin, a toning lotion, a vanishing cream, and any other pharmaceutical cream suitable for application to human skin, that can rejuvenate human skin will benefit those interested in maintaining a healthy skin that is youthful insofar as possible with minimal deleterious effects due to the course of time and concomitant exposure to stressors.

SUMMARY

The following is a broad summary of various exemplary embodiments of a topical skin cream composition for maintaining a healthy human skin.

According to an embodiment of the invention there is provided a topical skin cream composition comprising a nucleoprotein complex that adds a human specific telomere repeat sequence to a 3 ^' end of a human telomere.

In another embodiment, the nucleoprotein complex may comprise at least one catalytic subunit, at least one nucleic acid primer, and at least one small nucleolar ribonucleoprotein.

In another embodiment, the at least one catalytic subunit may be a telomere extending enzyme.

In another embodiment, the telomere-extending enzyme may be an RNA- directed DNA polymerase. In another embodiment, the RNA-directed DNA polymerase may be a telomerase reverse transcriptase.

In another embodiment, the telomerase reverse transcriptase may be a human telomerase reverse transcriptase.

In another embodiment, the human telomerase reverse transcriptase may be an enzyme designated by Enzyme Commission Number 2.7.7.49.

In another embodiment, the at least one nucleic acid primer may be a non coding RNA.

In another embodiment, the non-coding RNA may be a template for adding the human specific telomere repeat sequence to the 3 ^' end of the human telomere.

In another embodiment, the template may be a telomerase RNA component (TERC).

In another embodiment, the telomere-extending enzyme may be a DNA- directed DNA polymerase.

In another embodiment, the DNA-directed DNA polymerase may be a DNA- dependent DNA polymerase.

In another embodiment, the DNA-dependent DNA polymerase may be an enzyme designated by Enzyme Commission Number 2.7.7.7.

In another embodiment, the at least one nucleic acid primer may be a DNA primer.

In another embodiment, the DNA primer may be a template for adding the human specific telomere repeat sequence to the 3 ^' end of the human telomere.

In another embodiment, the human specific telomere repeat sequence may be a 5 ^' -3 ^' nucleotide sequence TTAGGG.

In another embodiment, the at least one small nucleolar ribonucleoprotein may be dyskerin.

In another embodiment, the topical skin cream composition may comprise a vesicle including therein the nucleoprotein complex.

In another embodiment, the topical skin cream composition may be a colloid.

In another embodiment, the colloid may be a liquid colloid.

In another embodiment, the vesicle may be a liposome.

In another embodiment, the liposome may be selected from the group consisting of: a cochleate-vesicle liposome, a large-unilamellar-vesicle liposome, a multilamellar-vesicle liposome, a multi vesicular liposome, and a small-unilamellar- vesicle liposome.

In another embodiment, the vesicle may be a micelle.

In another embodiment, the vesicle may be a supermicelle.

In another embodiment, the vesicle may be an inverse micelle.

In another embodiment, the topical skin cream composition may comprise a telomerase-activity modulator.

In another embodiment, the telomerase-activity modulator may be a telomerase-activity activator.

In another embodiment, the telomerase-activity activator may be selected from the group consisting of: astragaloside IV, broccoli seed extract, chia seed extract, chlorella powder extract, cycloastragenol, Cynomorium coccineum extract, dimethylaminoethanol L-bitartrate, Gingko biloba extract, ginseng extract, glycine, green tea extract, L-carnosine, milk thistle extract, /V-acetyl-L-cysteine hydrochloride, Portulaca oleracea extract, resveratrol, salidroside, vitamin D3, and a-lipoic acid.

Embodiments of the invention are now described, by way of example.

DETAILED DESCRIPTION

The present disclosure is directed, at least in part, to a topical skin cream composition that assists with the maintenance of a youthful appearance of human skin. More particularly, the present disclosure is directed to a topical skin cream composition for maintaining a healthy human skin that is youthful insofar as possible with minimal deleterious effects due to the course of time and concomitant exposure to stressors.

In an embodiment, the topical skin cream composition comprises a base in which vesicles comprising a nucleoprotein complex that adds a human specific telomere repeat sequence to a 3 ^' end of a human telomere are dispersed. Although not intending to be bound by this hypothesis, the nucleoprotein complex that adds a human specific telomere repeat sequence to a 3 ^' end of a human telomere mitigates the effects of normal ageing by facilitating the ongoing replenishment of skin cells such that a youthful skin tone is achieved. Preferably, the nucleoprotein complex comprises an RNA-directed DNA polymerase, namely the human telomerase reverse transcriptase designated by Enzyme Commission Number 2.7.7.49.

In a preferred embodiment, the vesicles typically will have a particle size range of 1 -100 mM, with a preferred particle size range of 1 -10 pM. The vesicles of the preferred embodiments will be liposomes or micelles. In particularly preferred embodiments, the vesicles are micelles that are smaller and more stable than the vesicles known to those in the cosmetics arts and typically used in topical skin cream compositions.

In a preferred embodiment, the base is an aqueous base.

In preferred embodiments, the topical skin cream composition will also comprise serum proteins. Typically, the serum proteins will be albumin and/or globulin or hydrolysed albumin and/or globulin. A person skilled in the art will also appreciate that embodiments of the skin cream composition may also include: amino acids or a pharmaceutically acceptable salts thereof, at least one antioxidant or a pharmaceutically acceptable salt thereof, caffeine or a pharmaceutically acceptable salt thereof, chlorphenesin or a pharmaceutically acceptable salt thereof, cholesterol or a pharmaceutically acceptable salt thereof, fatty acid esters or pharmaceutically acceptable salts thereof, fatty acids or pharmaceutically acceptable salts thereof, glyceryl ester complex, hydrolysed collagen or pharmaceutically acceptable salts thereof, hydrolysed glycosaminoglycans or pharmaceutically acceptable salts thereof, lactic acid or a pharmaceutically acceptable salt thereof, lecithin or a pharmaceutically acceptable salt thereof, methylparaben or a pharmaceutically acceptable salt thereof, palmitic acid or a pharmaceutically acceptable salt thereof, phenoxyethanol or a pharmaceutically acceptable salt thereof, phospholipids or a pharmaceutically acceptable salts thereof, plant extracts, polyethylene glycol or a pharmaceutically acceptable salt thereof, propylene glycol or a pharmaceutically acceptable salt thereof, stearic acid or a pharmaceutically acceptable salt thereof, succinic acid or a pharmaceutically acceptable salt thereof, tocopherol or a pharmaceutically acceptable salt thereof, urea or a pharmaceutically acceptable salt thereof, water, and white petrolatum. The preferred embodiments will also comprise a cosmetically acceptable fragrance known to those skilled in the cosmetic arts. These components of the topical skin cream composition, whose use is optional, impart additional desirable properties to the topical skin cream composition.

The ingredients of the topical skin cream composition are dispersed in the base using methods known to a person skilled in the cosmetic arts. Further, the ingredients are dispersed in a uniform manner that results in the nucleoprotein complex that adds a human specific telomere repeat sequence to a 3 ^' end of a human telomere distributing into vesicles in the base in a cosmetically effective concentration.

The following prophetic examples are made: Example 1

Liposomes with a preferred particle size range of 1 -10 mM comprising the human telomerase reverse transcriptase designated by Enzyme Commission Number

2.7.7.49 are mixed into an aqueous base comprising hydrolysed 3.0-5.0% human serum albumin. The aqueous base also comprises 0.3-0.5% palmitate, 1 .0-1 .8% cholesterol, 0.5-0.8% glyceryl stearate, 1 .0-2.5% plant extract (Jojoba nut oil), and 25.0-35.0% ultrapure water. The liposomes and aqueous base comprising the above- mentioned ingredients are mixed using commercial mixer known to those skilled in the cosmetics arts at a moderate rate in a stainless-steel mixing vessel. The mixing is continued until the liposomes and the aqueous base comprising the above-mentioned ingredients are uniformly mixed. The uniformly mixed colloidal mixture is dispensed into suitable containers for storage at a temperature of between 10-15°C.

Example 2

Micelles with a preferred particle size range of 1 -10 pM comprising the human telomerase reverse transcriptase designated by Enzyme Commission Number

2.7.7.49 are mixed into an aqueous base comprising hydrolysed 3.0-5.0% human serum albumin. The aqueous base also comprises 0.3-0.5% palmitate, 1 .0-1 .8% cholesterol, 0.5-0.8% glyceryl stearate, 1 .0-2.5% plant extract (Jojoba nut oil), and 25.0-35.0% ultrapure water. The micelles and aqueous base comprising the above- mentioned ingredients are mixed using commercial mixer known to those skilled in the cosmetics arts at a moderate rate in a stainless-steel mixing vessel. The mixing is continued until the micelles and the aqueous base comprising the above-mentioned ingredients are uniformly mixed. The uniformly mixed colloidal mixture is dispensed into suitable containers for storage at a temperature of between 10-15°C.

Example 3

Liposomes with a preferred particle size range of 1 -10 pM comprising the human telomerase reverse transcriptase designated by Enzyme Commission Number

2.7.7.49 are mixed into an aqueous base comprising hydrolysed 3.0-5.0% human serum albumin. The aqueous base also comprises 0.3-0.5% palmitate, 1 .0-1 .8% cholesterol, 0.5-0.8% glyceryl stearate, 1 .0-2.5% plant extract (Jojoba nut oil), 1 .0- 2.0% astragaloside IV, and 25.0-35.0% ultrapure water. The liposomes and aqueous base comprising the above-mentioned ingredients are mixed using commercial mixer known to those skilled in the cosmetics arts at a moderate rate in a stainless-steel mixing vessel. The mixing is continued until the liposomes and the aqueous base comprising the above-mentioned ingredients are uniformly mixed. The uniformly mixed colloidal mixture is dispensed into suitable containers for storage at a temperature of between 10-15°C.

Example 4

Micelles with a preferred particle size range of 1 -10 mM comprising the human telomerase reverse transcriptase designated by Enzyme Commission Number

2.7.7.49 are mixed into an aqueous base comprising hydrolysed 3.0-5.0% human serum albumin. The aqueous base also comprises 0.3-0.5% palmitate, 1 .0-1 .8% cholesterol, 0.5-0.8% glyceryl stearate, 1 .0-2.5% plant extract (Jojoba nut oil), 1 .0- 2.0% astragaloside IV, and 25.0-35.0% ultrapure water. The micelles and aqueous base comprising the above-mentioned ingredients are mixed using commercial mixer known to those skilled in the cosmetics arts at a moderate rate in a stainless-steel mixing vessel. The mixing is continued until the micelles and the aqueous base comprising the above-mentioned ingredients are uniformly mixed. The uniformly mixed colloidal mixture is dispensed into suitable containers for storage at a temperature of between 10-15°C.

Example 5

Liposomes with a preferred particle size range of 1 -10 pM comprising the human telomerase reverse transcriptase designated by Enzyme Commission Number

2.7.7.49 are mixed into an aqueous base comprising hydrolysed 3.0-5.0% human serum albumin. The aqueous base also comprises 0.3-0.5% palmitate, 1 .0-1 .8% cholesterol, 0.5-0.8% glyceryl stearate, 1 .0-2.5% plant extract (Jojoba nut oil), 1 .0- 2.0% cycloastragenol, and 25.0-35.0% ultrapure water. The liposomes and aqueous base comprising the above-mentioned ingredients are mixed using commercial mixer known to those skilled in the cosmetics arts at a moderate rate in a stainless-steel mixing vessel. The mixing is continued until the liposomes and the aqueous base comprising the above-mentioned ingredients are uniformly mixed. The uniformly mixed colloidal mixture is dispensed into suitable containers for storage at a temperature of between 10-15°C.

Example 6

Micelles with a preferred particle size range of 1 -10 pM comprising the human telomerase reverse transcriptase designated by Enzyme Commission Number

2.7.7.49 are mixed into an aqueous base comprising hydrolysed 3.0-5.0% human serum albumin. The aqueous base also comprises 0.3-0.5% palmitate, 1 .0-1 .8% cholesterol, 0.5-0.8% glyceryl stearate, 1 .0-2.5% plant extract (Jojoba nut oil), 1 .0- 2.0% cycloastragenol, and 25.0-35.0% ultrapure water. The micelles and aqueous base comprising the above-mentioned ingredients are mixed using commercial mixer known to those skilled in the cosmetics arts at a moderate rate in a stainless-steel mixing vessel. The mixing is continued until the micelles and the aqueous base comprising the above-mentioned ingredients are uniformly mixed. The uniformly mixed colloidal mixture is dispensed into suitable containers for storage at a temperature of between 10-15°C.

A person skilled in the art will appreciate that the composition of the above prophetic examples may be formulated to accommodate other physiologically acceptable skin creams, eye creams, sun tan lotions, and body lotions.

It is to be understood that the terminology employed above is for the purpose of description and should not be regarded as limiting. The described embodiments are intended to be illustrative of the invention, without limiting the scope thereof. The invention is capable of being practised with various modifications and additions as will readily occur to those skilled in the art.